semaglutide heart failure trial Oral Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Kidney and Survival Benefits of

Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that [PMID: 35668318] Laboratory literature summary: Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer

Retatrutide showed even more striking numbers in early-phase research

10.1038/s41418-024-01417-z 14 CovarrubiasA

Finding the best probiotic for GLP-1 support may provide modest benefits when combined with dietary and exercise changes

Treatment duration proves critical variable where longer courses create more durable changes - users completing 2-3 month treatments typically maintain 20-40% of peak benefits long-term, 4-6 month treatments sustain 40-60% of improvements, and 6-12+ month courses preserve 50-70% of maximum benefits potentially indefinitely